Ocugen, Inc. · Brief

Next report

3 days

Nov 4 · before openest.Q3 FY26

Expected move

No implied move.

—≥ implied

Q2 FY26±22.9%▼−3.13%×0.14

quarterimplied−25%0+25%realized×

Q2 FY26±22.9%▼−3.13%×0.14

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Nov 4 report · est.

Bull2 of 3

12disclosed supplier and customer ties in SEC filingsSEC filings

149managers reporting a position in the latest quarterly filings13F · Jun 30 '26

Bear2

0.20%of State Street SPDR S&P Biotech ETF's assets, the largest tracked fund weightN-PORT · Jun 30 '26

6 of 24of the largest reporting managers cut their stake in the latest quarter13F · Jun 30 '26

AI captions · Oct 26 '26once per report · top 2 per case

OCGN report session

No linked exposure.

Oct 21impliedImplied move: ±18.9% into Nov 4 earnings (Oct 21 close).Source

Oct 158-KMaterial agreement: Exclusive License Agreement with Roots Pharmaceutical Company WLL.Source

privateThesis 0 · Decisions 0 · Observations 0

No thesis.